

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of	)
Donald J. Zack	) Examiner: TBA
Serial No. 10/617,888	) Group Art Unit: 1632
Filed: July 14, 2003	)
For: NEURONAL AND OPTIC NERVE GENE EXPRESSION PATTERNS	) ) Atty. Dkt. No. 01107.00369

## INFORMATION DISCLOSURE STATEMENT 37 C.F.R. § 1.97(e)(1)

Commissioner for Patents Post Office Box 1450 Alexandria, Virginia 22313-1450

Submitted herewith is one (1) sheet of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97 (e)(1). The undersigned certifies that all items of information contained in the Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by the undersigned more than thirty days prior to the filing of this Information Disclosure Statement. It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge Deposit Account 19-0733.

Respectfully submitted,

Dated: July 12, 2004

Sarah A. Kagan

By:

Registration No. 32,141

Banner & Witcoff, Ltd. Customer No. 22907

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known			
Application Number	10/617,888		
Filing Date	July 14, 2003		
First Named Inventor	Donald J. ZACK		
Art Unit	1632		
Examiner Name	TBA		
Attorney Docket Number	001107.00369		

	U.S. PATENT DOCUMENTS				
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials * No.1		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
		US-5,874,082	01/21/1999	De Boer	
		US- 6,509,016	01/21/2003	Chatterjee et al.	
-		US-			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	ication Applicant of Cited Applicant of Cited Passages or Relevant	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY		Passages or Relevant Figures Appear	Τ <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		Phillips, K.E. et al. "IL-2Ra-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism Other than Blockade of IL-2/IL-2Ra Interaction," Cancer Research (Dec 15 2000), pp 6977-6984, Vol. 60		
		Yamada, T. et al. "Further Characterization of a Monclonal Antibody Recognizing Apolipoprotein E Peptides in Amyloid Deposits," Annals of Clinical and Laboratory Science (July/August 1997), pp. 276-281, Vol. 27, No. 4		
		Mogi, M. et al., "b2-Microglobulin decrease in cerebrospinal fluid from Parkinsonian patients," Neuroscience Letters (Sept 25, 1989), Vol. 104, No. 1-2, pp. 241-246		
		International Search Report PCT/US03/21738, dated July 1, 2004		

		1.00
Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.